Cargando…

2414. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in High-Risk Patients

BACKGROUND: Studies suggest oral vancomycin prophylaxis may be effective in preventing Clostridioides difficile infection. These studies are limited by their retrospective design, reliance on local clinical practice patterns, lack of intervention standardization, and limited risk stratification. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Steven W, Priest, David H, Brown, Shannon V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810079/ http://dx.doi.org/10.1093/ofid/ofz360.2092

Ejemplares similares

2433. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridioides difficile Infection in Critically Ill Patients
por: Vega, Ana D, et al.
Publicado: (2019)

2421. Efficacy of Secondary Prophylaxis with Oral Vancomycin in Preventing Recurrent Clostridioides difficile Infections in Patients Receiving Systemic Antibiotics
por: Pillinger, Kelly E, et al.
Publicado: (2019)

1376. Oral Vancomycin as Secondary Prophylaxis Against Clostridioides difficile Infection in Pediatric Patients
por: Bao, Hongkai, et al.
Publicado: (2020)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

213. Prophylactic oral vancomycin for Clostridioides difficile in allogeneic hematopoietic stem cell transplant recipients
por: Ogawa, Lauren, et al.
Publicado: (2022)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

Role of diagnostic stewardship in reducing healthcare facility-onset Clostridioides difficile infections
por: Shallal, Anita, et al.
Publicado: (2022)

Role of diagnostic stewardship in reducing healthcare-facility–onset Clostridioides difficile infections
por: Shallal, Anita B., et al.
Publicado: (2023)

696. Effectiveness of Oral Vancomycin as Prophylaxis against Clostridioides difficile Infection in Hematopoietic Stem Cell Transplant Patients
por: Reitmeyer, Kelly M, et al.
Publicado: (2023)

657. Impact of Oral Vancomycin Duration on Clostridioides difficile Recurrence in Patients Requiring Concurrent Systemic Antibiotics
por: Marsh, Kassandra, et al.
Publicado: (2023)

763. Impact of Two-Step Testing Algorithm on Hospital-onset Clostridioides difficile Infections and Oral Vancomycin Prescription Practices at an Academic Medical Center
por: Wingler, Mary Joyce, et al.
Publicado: (2021)

2412. Oral Vancomycin Prophylaxis Against Recurrent Clostridioides difficile Infection: Efficacy and Side-effects: Two Hospitals Experience
por: Zacharioudakis, Ioannis, et al.
Publicado: (2019)

2411. One Dose Vancomycin Prophylaxis for In-Hospital Clostridioides difficile - Associated Disease
por: Papic, Neven, et al.
Publicado: (2019)

380. A molecular epidemiological exploration of reduced vancomycin susceptibility in Clostridioides difficile
por: Eubank, Taryn A, et al.
Publicado: (2022)

Utilizing vancomycin as secondary prophylaxis for the prevention of recurrent Clostridioides difficile infection
por: Kristen, Zeitler, et al.
Publicado: (2023)

2164. Resistome patterns associated with vancomycin non-susceptibility in clinical Clostridioides difficile isolates
por: Eubank, Taryn A, et al.
Publicado: (2023)

2413. Assessment of compliance with Clostridioides difficile prophylaxis guideline and its efficacy on secondary prophylaxis and reducing hospital-onset Clostridioides difficile infections.
por: Vyas, Nikunj M, et al.
Publicado: (2019)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

800. Oral Vancomycin Prophylaxis Against Clostridioides difficile in Patients Admitted to a Tertiary Academic Medical Center
por: Kopelman, David B, et al.
Publicado: (2020)

680. Comparison of Extended Duration Vancomycin Regimens for Clostridioides difficile Infection in Patients on Prolonged Antibiotic Courses
por: Garzia, Christopher, et al.
Publicado: (2023)

Initial Oral Vancomycin vs. Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection
por: Shah, Sunish, et al.
Publicado: (2017)

Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2021)

658. Oral Vancomycin Taper for First Occurrence of Clostridioides difficile Compared to Standard of Care: An Observational Retrospective Matched Cohort Study
por: Moore, Sarah E, et al.
Publicado: (2023)

391. Evaluation of oral vancomycin treatment for hospital-acquired Clostridioides difficile infection prophylaxis in a community hospital: A retrospective cohort study
por: Meng, Qingqing, et al.
Publicado: (2022)

1203. Impact of Antimicrobial Stewardship Interventions on Hospital-Onset Clostridioides difficile Infections
por: Kwon, Taesung, et al.
Publicado: (2023)

Assessment of independent comorbidities and comorbidity measures in predicting healthcare facility-onset Clostridioides difficile infection in Kenya
por: Mutai, Winnie C., et al.
Publicado: (2022)

400. Rehospitalization of Patients for Recurrent Clostridioides difficile Infection
por: Drwiega, Emily, et al.
Publicado: (2022)

Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients
por: Fishbein, Skye R. S., et al.
Publicado: (2021)

670. Clinical Characteristics and Outcomes in Patients with Healthcare Facility-Onset Clostridiodes difficile Infections
por: Joshi, Seema, et al.
Publicado: (2023)

2430. Comorbidity and Severity of Illness Risk Adjustment for Hospital-Onset Clostridioides difficile Infection
por: Cabral, Stephanie, et al.
Publicado: (2019)

382. Are errors of omission falsely inflating hospital-onset Clostridioides difficile infection numbers?
por: Parada, Jorge Paiva, et al.
Publicado: (2022)

753. Impact of COVID-19 on Healthcare Facility-Onset Clostridiodes difficile Infection
por: Suleyman, Geehan, et al.
Publicado: (2021)

P18 Audit on compliance with the preventive measures on Clostridioides difficile
por: Marques Reis, I, et al.
Publicado: (2023)

1628 Accuracy of Healthcare Facility-Onset Clostridium difficile Classification
por: Trappler, Regan, et al.
Publicado: (2014)

668. The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection in immunocompromised hosts, a single center study
por: Alsoubani, Majd, et al.
Publicado: (2023)

669. The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection, a single center real-world experience
por: Alsoubani, Majd, et al.
Publicado: (2023)

88. Impact of a Computerized Clinical Decision Support Tool on clostridioides Difficile Testing and Oral Vancomycin Utilization as a Balancing Metric
por: Hussain, Cory, et al.
Publicado: (2020)

2414. Pulling the Cord: Removal of Urinary Catheters before Urine Culture in a Cardiothoracic-Surgery ICU
por: Ben-Aderet, Michael, et al.
Publicado: (2023)

A Multi-Pronged Approach to Control Healthcare Facility-Onset Clostridium difficile Infection in a Tertiary Care Community Hospital
por: Chinn, Raymond, et al.
Publicado: (2017)

488. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridium difficile Infection in Critically Ill Patients
por: Vega, Ana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0ro2rqv3rlid680b9cg13367mb